BridgeMD
MAMI Use of the Methoxyflurane as pain-killer in the prehospital management of Acute Myocardial Infarction
EU CTIS ID: 2023-507296-21-00
What this study is testing
To demonstrate that methoxyflurane self-administered by the patient suffering chest pain related to an acute myocardial infarction is at least as efficient in achieving pain relief that morphine with better tolerance.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient age ≥ 18 years
- Patient managed in pre-hospital setting for a ST elevation myocardial infarction (STEMI) : Douleur thoracique < 12 heures avec douleur modérée à sévère (EVA > 6/10).
- Patient managed in pre-hospital setting for a ST elevation myocardial infarction (STEMI): STEMI on EKG according to 2018 ESC guidelines
You likely can't join if
- Previous analgesic treatment for this episode of chest pain
- - Clinical evidence of cardiovascular instability (PAS <90 mm Hg)
- Altered level of consciousness due to any cause, including head trauma, drug or alcohol use.
- Clinically significant renal impairment.
- History of signs of liver damage after use of methoxyflurane or after anesthesia with a halogenated hydrocarbon.
- Severe hepatocellular insufficiency (with encephalopathy),,
See the full eligibility criteria
- Patient age ≥ 18 years
- Patient managed in pre-hospital setting for a ST elevation myocardial infarction (STEMI) : Douleur thoracique < 12 heures avec douleur modérée à sévère (EVA > 6/10).
- Patient managed in pre-hospital setting for a ST elevation myocardial infarction (STEMI): STEMI on EKG according to 2018 ESC guidelines
- Previous analgesic treatment for this episode of chest pain
- - Clinical evidence of cardiovascular instability (PAS <90 mm Hg)
- Altered level of consciousness due to any cause, including head trauma, drug or alcohol use.
- Clinically significant renal impairment.
- History of signs of liver damage after use of methoxyflurane or after anesthesia with a halogenated hydrocarbon.
- Severe hepatocellular insufficiency (with encephalopathy),,
- Acute head trauma and intracranial hypertension in the absence of controlled ventilation,
- Uncontrolled epilepsy
- Treatment with buprenorphine, nalbuphine and pentazocine, xyrem, naltrexone,
- Breastfeeding, in case of initiation or continuation after birth of a long-term treatment.
- Malignant hyperthermia: known malignant hyperthermia or genetic predisposition of the patient.
- Contra-indication to morphine or methoxuflurane administration
- History of serious adverse effects of the patient or his family after administration of inhaled anesthetics.
- Incapacity to self-assess pain intensity
- Incapacity to methoxyflurane self-administration
- Pregnancy, minors or incapacity (tutelle, curatelle)
- Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants
- Absence of a Social Security
- Clinical evidence of respiratory depression.
- Decompensated respiratory failure (in the absence of artificial ventilation),
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.